Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin

Nektar Therapeutics (NASDAQ:NKTR) is one of the Stocks With Huge Catalysts on the Horizon. On June 24, Nektar Therapeutics (NASDAQ:NKTR) announced positive results from the Phase 2b REZOLVE-AD trial of Rezpegaldesleukin to treat moderate-to-severe atopic dermatitis.

The drug showed significant improvement in Eczema Area and Severity Index scores after 16 weeks compared to placebo. Some notable points from the results include a 75% reduction in EASI, itch reduction, body surface area affected, and physician-assessed severity scores. The results highlighted that these improvements appeared quickly after starting treatment, helping differentiate this therapy from existing options.

Moreover, Rezpegaldesleukin also led to strong, dose-dependent reductions in inflammatory markers tied to atopic dermatitis, including TARC/CCL17 and IL-19. Management noted that this shows that the treatment works using a unique Treg (regulatory T-cell) mechanism, which could be a first in its class. Nektar Therapeutics (NASDAQ:NKTR) plans to present these findings at medical conferences later in 2025, whereas the long-term maintenance data are expected in early 2026.

Nektar Therapeutics (NASDAQ:NKTR) is a clinical-stage biotech company developing therapies that target immune system dysfunction in autoimmune, inflammatory diseases, and cancer.

While we acknowledge the potential of NKTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.